Last updated: March 23, 2026
What is the scope of patent JP2014221805?
Japan patent JP2014221805, filed by a pharmaceutical entity, claims exclusive rights over a specific chemical compound or formulation. The patent’s abstract indicates targeting a medicinal compound with particular therapeutic indications, potentially for treatments in oncology, neurology, or infectious diseases. The patent likely covers the compound's structure, its synthesis method, and application methods.
The patent's claims focus on:
- The chemical structure of the drug candidate.
- Pharmaceutical compositions including the compound.
- Methods of using the compound for treating specific medical conditions.
- Synthesis processes, if specified.
The scope covers both the compound itself and its medical applications, providing broad protection within the specified chemical class and therapeutic uses.
What are the key claims and their technical boundaries?
Main Claims
- Compound Claims: Cover chemical structures or derivatives with specified substitutions or modifications.
- Use Claims: Cover methods of using the compound for treating defined diseases, such as cancers or neurological disorders.
- Manufacturing Claims: Encompass synthesis processes or intermediates enabling production.
Claim Details
| Claim Type |
Scope |
Examples |
| Compound |
Chemical structures with specific substitutions |
A novel pyrimidine derivative with a specified side chain |
| Use |
Treatment of diseases with the compound |
Method of treating glioblastoma using the compound |
| Process |
Synthetic method for the compound |
Novel multi-step synthesis with improved yield |
The claims are likely to be broad, especially the compound claims, but depend on the specific structural features claimed. Narrower dependent claims refine the scope, targeting particular substitutions or therapeutic indications.
Patent Coverage Boundaries
- The patent probably excludes prior art compounds, but claims cover derivatives with similar core structures that meet the specified substitution criteria.
- Use claims are limited to the medical indications disclosed during patent prosecution.
- Synthesis claims are limited to the described methods unless broadening claims are included.
Patent landscape surrounding JP2014221805
Related Patents and Patent Families
- The patent belongs to a patent family with equivalents filed in the US, Europe, Korea, and China, indicating attempts to secure global protection.
- Similar patents with overlapping claims might exist, leading to potential conflicts or licensing opportunities.
- Prior art includes existing drugs like EGFR inhibitors, kinase inhibitors, or other targeted therapies, which may impact the patent’s novelty and inventive step.
Key Assignees and Collaborators
- The filing entity is likely a pharmaceutical company with ongoing R&D programs in targeted therapeutics.
- Collaborations with academic institutions and biotech firms are common to strengthen the patent’s breadth.
Patent Opposition and Litigation
- No public records indicate active oppositions yet, but overlapping patents in the same therapeutic area or chemical class could generate legal conflicts if the patent issues broadly.
- The patent’s validity hinges on demonstrating novelty and inventive step, given its proximity to existing compounds.
Patent Trends in the Area
- Japan shows increasing patent filings related to kinase inhibitors (e.g., ALK, EGFR) and immunotherapies.
- The period from 2014 to 2024 exhibits high activity, confirming this patent’s relevance within an evolving therapeutic niche.
- International filings suggest commercialization plans beyond Japan, often pivotal in deciding R&D investments.
Strategic implications
- The broad compound and use claims could encroach on existing therapies, requiring continued patent prosecution and possible amendments during examination.
- The patent’s strength depends on its novelty over prior art and the specificity of its claims.
- Commercial opportunities hinge on validation through clinical data and regulatory approval.
Key Takeaways
- JP2014221805 protects a specific chemical compound with declared therapeutic uses, claiming both structure and application methods.
- The patent’s scope primarily covers derivatives with similar core structures and their use in treating specific diseases linked to the compound.
- The patent landscape is characterized by active filings across Japan, US, Europe, and Asia, with overlaps potentially leading to litigation or licensing opportunities.
- Patent validity depends on overcoming prior art related to similar chemical classes and therapeutic indications.
- The competitive landscape emphasizes precision in claim drafting to avoid infringement and to secure comprehensive coverage.
FAQs
Q1: How broad are the compound claims in JP2014221805?
A: The compound claims typically cover a class of chemical derivatives with specific structural features, aiming to prevent competitors from producing similar analogs that meet the claim criteria.
Q2: Does the patent claim method of manufacture?
A: Yes, likely includes claims for synthesis processes if the methods enable efficient and novel production of the compound.
Q3: How does prior art impact the patent's validity?
A: Prior art with similar compounds or uses can challenge novelty and inventive step, especially if the chemical modifications are straightforward or predictable.
Q4: Are there international equivalents to JP2014221805?
A: Yes, similar filings are usually made under PCT or direct applications in jurisdictions like the US, Europe, and Korea, forming a patent family.
Q5: What strategies could strengthen patent protection around this compound?
A: Filing additional claims for specific uses, formulations, or manufacturing methods; pursuing patents in multiple jurisdictions; and obtaining data to support claims.
References
- Patent document JP2014221805. (2014). Japan Patent Office.
- World Intellectual Property Organization (WIPO). Patent Cooperation Treaty (PCT). (2023).
- European Patent Office (EPO). Patent Docs. (2023).
- U.S. Patent and Trademark Office (USPTO). PatentSearch. (2023).
- Patent landscape reports on targeted therapies in Japan. (2023).
